Acquisition by Janus Henderson Group Plc of 94537 shares of ARCA Biopharma at 3.4516 subject to Rule 16b-3
About 67% of ARCA Biopharma's investor base is looking to short. The analysis of current outlook of investing in ARCA Biopharma suggests that many traders are alarmed regarding ARCA Biopharma's prospects. ARCA Biopharma's investing sentiment overview a quick insight into current market opportunities from investing in ARCA Biopharma. Many technical investors use ARCA Biopharma stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
ARCA |
Filed transaction by ARCA Biopharma 10 Percent Owner. Grant, award or other acquisition pursuant to Rule 16b-3(d)
Read at macroaxis.com
ARCA Biopharma Fundamental Analysis
We analyze ARCA Biopharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ARCA Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ARCA Biopharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Total Asset
Total Asset Comparative Analysis
ARCA Biopharma is currently under evaluation in total asset category among its peers. Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value.
ARCA Biopharma Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with ARCA Biopharma stock to make a market-neutral strategy. Peer analysis of ARCA Biopharma could also be used in its relative valuation, which is a method of valuing ARCA Biopharma by comparing valuation metrics with similar companies.
Peers
ARCA Biopharma Related Equities
ANTX | AN2 Therapeutics | 21.90 | ||||
FBRX | Forte Biosciences | 9.70 | ||||
KTTA | Pasithea Therapeutics | 6.55 | ||||
CTMX | CytomX Therapeutics | 3.92 | ||||
QNRX | Quoin Pharmaceuticals | 1.69 | ||||
ADAG | Adagene | 1.30 | ||||
RZLT | Rezolute | 1.00 | ||||
SPRO | Spero Therapeutics | 0.88 | ||||
ACRV | Acrivon Therapeutics, | 0.80 | ||||
RNXT | RenovoRx | 0.79 | ||||
AVTE | Aerovate Therapeutics | 0.38 | ||||
INDP | Indaptus Therapeutics | 0.97 | ||||
TPST | Tempest Therapeutics | 1.04 | ||||
NXTC | NextCure | 2.50 | ||||
TIL | Instil Bio | 9.39 |
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Other Consideration for investing in ARCA Stock
If you are still planning to invest in ARCA Biopharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the ARCA Biopharma's history and understand the potential risks before investing.
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
Commodity Directory Find actively traded commodities issued by global exchanges | |
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital |